Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
The Effect of Anakinra on Insulin Secretion
- Conditions
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT01285232
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis
- Conditions
- First Posted Date
- 2011-01-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT01277315
- Locations
- 🇩🇪
Charité University Hospital, Berlin, Germany
A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
- Conditions
- Interventions
- First Posted Date
- 2010-12-29
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Andrea Vambutas
- Target Recruit Count
- 13
- Registration Number
- NCT01267994
- Locations
- 🇺🇸
North Shore-LIJ Hearing and Speech Center, New Hyde Park, New York, United States
Anakinra to Prevent Adverse Post-infarction Remodeling (2)
- Conditions
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 30
- Registration Number
- NCT01175018
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Anakinra in Myositis
- Conditions
- First Posted Date
- 2010-07-19
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Karolinska Institutet
- Registration Number
- NCT01165008
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
- Conditions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 1
- Registration Number
- NCT01122914
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study
- First Posted Date
- 2009-12-16
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 23
- Registration Number
- NCT01033656
- Locations
- 🇸🇪
Ann Kataja Knight, Uppsala, Sweden
Topical IL-1-Ra for Treatment of Corneal Neovascularization
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Reza Dana, MD
- Target Recruit Count
- 10
- Registration Number
- NCT00915590
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Anakinra to Prevent Post-infarction Remodeling
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 10
- Registration Number
- NCT00789724
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Anti-Interleukin-1 in Diabetes Action
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 69
- Registration Number
- NCT00711503
- Locations
- 🇪🇸
Hospital de Cruces, Diabetes Research Group, Barakaldo, Bizkaia, Spain
🇳🇱Leiden University Medical Center, Leiden, Netherlands
🇨🇭University Hospital Zürich, Zürich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.